Dernières nouvelles pour Stryker (NYSE:SYK) Stock

Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Stryker Corp

SOLITON SYSTEMS KK ORD by Soliton Systems

Soliton Systems KK

SKY NETWORK TV by Sky Network Television Ltd.

Sky Network Television Ltd

Spencer S Stiles, Group President at Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), executed a substantial insider sell on November 18, according to an SEC filing.
What Happened: Stiles's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000310764/000031076424000119//Archives/edgar/data/310764/000031076424000119/0000310764-24-000119-index.htm">U.S. Securities and Exchange Commission</a> on Monday unveiled the sale of 514 shares of Stryker. The total transaction value is $201,056.
Stryker shares are trading up 0.07% at $389.67 at the time of this writing on Tuesday morning.
<h3>Delving into Stryker's Background</h3>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>A Deep Dive into Stryker's Financials</h3>
Revenue Growth: Over the 3 months period, Stryker showcased positive performance, achieving a revenue growth rate of 11.92% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: Achieving a high gross margin of 64.02%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Stryker's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 2.18.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.77, caution is advised due to increased financial risk.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 41.74 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 6.82 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 29.39, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Deciphering Transaction Codes in Insider Filings</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000310764">Check Out The Full List Of Stryker's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

Stryker Recent Insider Activity

A substantial insider sell was reported on November 7, by Ronda E Stryker, Board Member at Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), based on the recent SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000310764/000031076424000117//Archives/edgar/data/310764/000031076424000117/0000310764-24-000117-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Stryker sold 230,000 shares of Stryker. The total transaction value is $84,494,989.
As of Friday morning, Stryker shares are up by 0.64%, currently priced at $372.19.
<h3>Get to Know Stryker Better</h3>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>Stryker's Financial Performance</h3>
Revenue Growth: Stryker's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.92%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 64.02%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.18, Stryker showcases strong earnings per share.
</li>
</ul>
Debt Management: Stryker's debt-to-equity ratio surpasses industry norms, standing at 0.77. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: Stryker's P/E ratio of 39.64 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.48, Stryker's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 28.01, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Exploring Key Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000310764">Check Out The Full List Of Stryker's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member At Stryker Sells $84.49M Of Stock

On November 5, it was revealed in an SEC filing that Yin C Becker, VP at Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) executed a significant exercise of company stock options.
What Happened: Becker, VP at Stryker, made a strategic move by exercising stock options for 4,980 shares of SYK as detailed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000310764/000031076424000116//Archives/edgar/data/310764/000031076424000116/0000310764-24-000116-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $1,340,815.
During Wednesday's morning session, Stryker shares down by 0.35%, currently priced at $365.88. Considering the current price, Becker's 4,980 shares have a total value of $1,340,815.
<h3>Discovering Stryker: A Closer Look</h3>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>Stryker's Economic Impact: An Analysis</h3>
Revenue Growth: Over the 3 months period, Stryker showcased positive performance, achieving a revenue growth rate of 11.92% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 64.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Stryker's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 2.18.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.77, caution is advised due to increased financial risk.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 39.64 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.48, Stryker's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 28.01 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000310764">Check Out The Full List Of Stryker's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options Exercise: Yin C Becker At Stryker Realizes $1.34M

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>).
On Oct. 29, Citigroup analyst Jon Tower maintained Cava Group with a Neutral and raised the price target <a href="https://www.benzinga.com/quote/CAVA/analyst-ratings">from $115 to $140.</a>
When asked about GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), he said, &#8220;You have to have planes last longer. And that means more GE business.&#8221;
On Oct. 22, GE Aerospace reported third-quarter 2024 adjusted revenue growth of 6% year-over-year to $8.943 billion and GAAP revenue of $9.84 billion. The analyst consensus was $9.022 billion.
Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is a &#8220;really good&#8221; company,&#8221; Cramer said. &#8220;It's just one of those companies that you just want to own it — I hate to say this — and forget about it, because that's how good it is.&#8221;
On Oct. 22, Stryker reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $2.77 per share. The company reported quarterly sales of $5.49 billion which beat the analyst consensus estimate of $5.37 billion.
Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) is &#8220;very good,&#8221; he said. &#8220;It's a great place to be, particularly with all the things that are being done with AI.&#8221;
Lantheus Holdings will host a conference call on Wednesday, Nov. 6, to discuss its financial and operating results for the third quarter.
Essential Utilities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) is a &#8220;great&#8221; company, the Mad Money host said. &#8220;That is a terrific stock.&#8221;
Essential Utilities will report earnings for the quarter ending Sept. 30, after the closing bell on Nov. 4.
Price Action:
<ul>
<li>GE Aerospace shares fell 1.6% to settle at $171.78 on Thursday.</li>
<li>Stryker shares dipped 2% to close at $356.28 on Thursday.</li>
<li>Lantheus shares gained 0.4% to settle at $109.84 during the session.</li>
<li>Essential Utilities fell 0.4% to settle at $38.60 on Thursday.</li>
<li>Cava shares fell 0.2% to close at $133.56.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

CAVA

LNTH

WTRG

Jim Cramer Likes Cava Group, Calls This Utilities Stock 'Terrific'

Citigroup analyst Joanne Wuensch maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $406 to $411.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Stryker, Raises Price Target to $411

Barclays analyst Matt Miksic maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $402 to $418.

Barclays Maintains Overweight on Stryker, Raises Price Target to $418

BTIG analyst Ryan Zimmerman maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $383 to $394.

BTIG Maintains Buy on Stryker, Raises Price Target to $394

Canaccord Genuity analyst Kyle Rose maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $360 to $400.

Canaccord Genuity Maintains Buy on Stryker, Raises Price Target to $400

RBC Capital analyst Shagun Singh maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $386 to $400.

RBC Capital Maintains Outperform on Stryker, Raises Price Target to $400

Piper Sandler analyst Matt O'Brien reiterates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $380 to $420.

Reiteration

Piper Sandler Reiterates Overweight on Stryker, Raises Price Target to $420

JP Morgan analyst Robbie Marcus maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $375 to $420.

JP Morgan Maintains Overweight on Stryker, Raises Price Target to $420

Truist Securities analyst Richard Newitter maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Hold and raises the price target from $370 to $380.

Truist Securities Maintains Hold on Stryker, Raises Price Target to $380

Evercore ISI Group analyst Vijay Kumar maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $380 to $384.

Evercore ISI Group Maintains Outperform on Stryker, Raises Price Target to $384

Wells Fargo analyst Larry Biegelsen maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $381 to $405.

Wells Fargo Maintains Overweight on Stryker, Raises Price Target to $405

UBS analyst Danielle Antalffy maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Neutral and raises the price target from $366 to $370.

UBS Maintains Neutral on Stryker, Raises Price Target to $370

During the last three months, 8 analysts shared their evaluations of Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Stryker, presenting an average target of $388.25, a high estimate of $409.00, and a low estimate of $370.00. This current average reflects an increase of 4.73% from the previous average price target of $370.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1730289628_0_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Stryker among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$405.00</td>
<td>$378.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$409.00</td>
<td>$393.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$383.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$370.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$405.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$374.00</td>
<td>$360.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Stryker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stryker compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Stryker's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Stryker's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SYK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Stryker analyst ratings.</a>
<h2>Get to Know Stryker Better</h2>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>Stryker: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Stryker showcased positive performance, achieving a revenue growth rate of 8.53% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Stryker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Stryker's ROE excels beyond industry benchmarks, reaching 4.24%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Stryker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.1% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Stryker's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.62.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Stryker's Future

Baird analyst Jeff Johnson maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $378 to $405.

Baird Maintains Outperform on Stryker, Raises Price Target to $405

Needham analyst Mike Matson maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $393 to $409.

Needham Maintains Buy on Stryker, Raises Price Target to $409

WIIM

Stryker shares are trading higher after the company reported better-than-expected Q3 financial results.

Earnings

Guidance

Stryker Sees Q4 2024 Adj. Net Earnings Per Diluted Share $12-$12.10

Wells Fargo's 'Focus List' – GOOGL, TJX, XOM, JPM

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2024 Update

Bank of America Securities analyst Travis Steed maintained a Buy rating on Stryker (SYK – Research Report) today. The company's shares opened today...

Stryker (SYK) Receives a Buy from Bank of America Securities

The medical device sector is evolving, driven by rising demand for precision technology in diagnostics. Therefore, it could be ideal to buy fundamentally solid medical device stocks Stryker Corp (SYK), Axogen (AXGN), and Zimmer Biomet Holdings (ZBH), which look poised for substantial growth. Read more… With an aging population and a rise in chronic health issues, medical technology innovations are rapidly becoming essential in healthcare, enabling quicker diagnoses and improved patient outcomes. The medical device industry is experiencing dynamic growth fueled by advancements in technology and increasing demand for innovative healthcare solutions.
Given this landscape, investors might consider investing in three fundamentally strong medical devices stocks, Stryker Corporation (<a href="https://stocknews.com/stock/SYK/">SYK</a>), Axogen, Inc. (<a href="https://stocknews.com/stock/AXGN/">AXGN</a>), and Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), that are well-positioned for potential growth.
Medical device companies specializing in surgical robotics, imaging, diagnostics, and portable health monitoring devices are delivering innovative products that meet the rising demand for efficient and less invasive treatments. The <a href="https://blog.bccresearch.com/the-growing-market-for-elderly-and-disabled-assistive-devices">key market driver in this sector</a> is the aging population, rising awareness and accessibility, and a surge in technological advancements.
As per the <a href="https://www.medicaldevice-network.com/sponsored/ageing-in-the-digital-era-the-surge-of-medical-device-innovation-for-older-adults/">World Health Organization (WHO), the global population aged 60</a> and above will double to 2.1 billion by 2050. This demographic shift means the role of medical devices will be more crucial than at other times in history.
Healthcare providers and patients alike are prioritizing convenience and precision, pushing for technologies that aid in real-time monitoring and minimally invasive procedures. The <a href="https://www.advamed.org/medical-device-industry-facts/">United States is the largest medical device market in the world</a>, compromising over 40% of the global MedTech market, providing physicians and other healthcare providers with the best tools to diagnose and treat patients.
According to a KPMG report, the medical device industry is poised for steady growth, with global <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html">annual sales forecasted to reach nearly $800 billion by 2030</a>, with a rise of over 5% a year. Companies in this space benefit from long-term demand as healthcare spending remains resilient.
Now, let's take a closer look at the fundamentals of the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> stocks mentioned above, beginning with the third choice.
Stock #3: Stryker Corporation (<a href="https://stocknews.com/stock/SYK/">SYK</a>)
Stryker Corporation operates as a medical technology company. The company operates through two segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. 
On October 1, SYK announced the completion of the <a href="https://www.investopedia.com/terms/a/acquisition.asp">acquisition</a> of its Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. This acquisition enhances non-surgical solutions with minimal invasive wild procedures for SYK.   
On September 17, SYK announced that it completed its acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology, and ambient intelligence solutions. This acquisition should strengthen Stryker's growing healthcare IT offering and wirelessly connected medical device portfolio.
In the fiscal third quarter that ended on September 30, 2024, SYK's net sales increased 11.9% year-over-year to $5.49 billion. The company reported an operating income of $2.43 billion, indicating a 9.2% growth from the prior-year quarter.
SYK's adjusted net earnings came in at $1.11 billion, up 17.3% year-over-year, while its adjusted earnings per share grew 16.7% from the year-ago value to $2.87.
For the full year 2024, SYK expects organic net sales to be in the range of 9.5% to 10% and adjusted net earnings diluted per share to range from $12 to $12.10.
The consensus revenue estimate of $6.36 billion for the fiscal first quarter (ending December 2024) represents a 9.4% increase year-over-year. The consensus EPS estimate of $3.87 for the same quarter indicates an 11.9% improvement year-over-year. The company has an excellent surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Moreover, SYK's revenue has grown at CAGRs of 9.7% and 8.6% over the past three and five years, respectively. In addition, its EBIT increased at 8.4% CAGR over the past three years.
Over the past year, the stock has surged 33.3%, closing the last trading session at $369.02.
SYK's stance is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has a B grade for Growth, Stability, and Sentiment. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry, it is ranked #46. <a href="https://stocknews.com/stock/SYK/">Click here</a> to see the additional SYK ratings (Value, Momentum, and Quality).
Stock #2: Axogen, Inc. (<a href="https://stocknews.com/stock/AXGN/">AXGN</a>)
AXGN develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator, and Axoguard HA+ Nerve Protector.
On June 24, AXGN launched Avive+ Soft Tissue Matrix&#x2122;, which is used for a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. This launch is a new opportunity to improve patient outcomes after acute traumatic injury.
During the third quarter that ended on September 30, 2024, AXGN's revenue increased 17.9% year-over-year to $48.64 million. The company's gross profit amounted to $36.44 million, reflecting an increase of 14.9% from the prior-year quarter.
Its adjusted EBITDA of $6.49 million, indicating a 175.6% growth from the prior-year quarter. In addition, AXGN's adjusted net income amounted to $3.15 million and $0.07 per share, reflecting considerable increases year-over-year.
Looking ahead, AXGN anticipates annual revenue for fiscal year 2024 to fall between $182 million and $186 million. The company also projects gross margin to be in the range of 74% to 76%.
Analysts expect AXGN's revenue for the fiscal year (ending December 2024) to increase 16.1% year-over-year to $184.60 million.
Over the past three and five years, AXGN's revenue income grew at CAGRs of 9.9% and 12.5%, respectively, while its total assets grew at 3.8% CAGR over the past five years.
The stock has gained 290.1% over the past year and 170.4% over the past six months to close the last trading session at $15.33.
AXGN's POWR Ratings reflect its promising outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system.
AXGN has an A grade for Growth and B for Sentiment. It is ranked #35 in the Medical - Devices &amp; Equipment industry. <a href="https://stocknews.com/stock/AXGN/">Click here</a> to see the other ratings of AXGN for Value, Momentum, Stability, and Quality.
Stock #1: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH is a global medical technology company that designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products.
On August 7, ZBH signed an agreement to acquire OrthoGrid Systems, Inc., a privately held medical technology company focused on AI-driven surgical guidance systems for total hip replacement. This acquisition will help ZBH address the challenges of orthopedic problems with innovative technology solutions.
For the third quarter of 2024, which ended on September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. Its operating profit rose 4.8% from the year-ago value to $279.50 million. The company's adjusted net earnings stood at $353.20 million, up marginally year-over-year, while its adjusted EPS for the quarter increased 5.5% year-over-year to $1.74.
According to the company's financial guidance for fiscal year 2024, ZBH forecasts revenue between 3.5%-4%. The company also expects adjusted diluted EPS to be between $7.95 and $8.05.
Street expects ZBH's revenue for the fiscal fourth quarter (ending December 2024) to increase 3.9% year-over-year to $2.02 billion. Its EPS for the same period is expected to register a 4.3% growth from the prior year, settling at $2.30. In addition, it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters, which is excellent.
ZBH's normalized net income has grown at CAGRs of 8.7% and 3.8% over the past three and five years, respectively. Likewise, the company's levered FCF has increased at a CAGR of 2.2% over the past five years.
ZBH's stock has surged 5.2% over the past month to close the last trading session at $110.17.
ZBH's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Growth and Value. Within the same industry, it is ranked #17 out of 328 stocks. <a href="https://stocknews.com/stock/ZBH/">Click here</a> to see ZBH's ratings for Momentum, Stability, Sentiment, and Quality.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
SYK shares were trading at $369.10 per share on Thursday afternoon, up $0.08 (+0.02%). Year-to-date, SYK has gained 24.10%, versus a 26.40% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/syk-zbh-axgn-3-medical-devices-stocks-poised-for-solid-growth/>3 Medical Devices Stocks Poised for Solid Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Devices Stocks Poised for Solid Growth

Medtech shouldn't be greatly impacted by RFK Jr. at HHS, Wells Fargo says

This momentum indicator says the S&P won't peak until next year

Globus Medical Stock: Re-Rated After A Solid Year

Fidelity Select Health Care Portfolio Q3 2024 Fund Review

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

Piper Sandler Reaffirms Their Buy Rating on Stryker (SYK)

AAPL

ABBV

ADBE

AGNC

ALGN

ALIZF

ALNY

AMZN

ARCC

ARGNF

ARGX

ASML

ASMLF

AVGO

AXGN

BABA

BASFY

BAYZF

BLUE

BXSL

CBAUF

CSCO

CSGP

CSWC

CTAS

DXCM

EXAS

EXPD

GAIN

GILD

GLAD

GMED

GOOD

GOOG

GOOGL

GSBD

HTGC

IDXX

INTC

INTU

MAIN

MCHP

MFIC

MSFT

NEWT

NFLX

NVDA

OBDC

PANW

PCVX

PODD

RITM

SCHW

SEMHF

SHEL

SPGI

STAG

STWD

TMUS

TSMWF

UNIT

WELL

XLRE

Screenshot 2024-09-30 at 5.38.54 PM

Biotech

Movers & Shakers

General

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2024-03-18 at 5.30.26 PM

Health Care

MGRM

Monogram Orthopaedics (NASDAQ: MGRM) Aims To Overcome Robot Shortcomings With Its Advanced Solution

Press Releases

Stryker completes acquisition of Vertos Medical, Inc., expanding interventional pain management solutions

How Cosmos Health's Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Stryker to announce its third quarter 2024 financial results

Legal

Treace Files Patent Infringement and Unfair Competition Suit to Protect Lapiplasty® Bunion Technology

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Stryker reports third quarter 2024 operating results

Stryker launches next generation of SurgiCount+ to help improve the standard of care in hospitals for sponge management and blood loss assessment

Stryker unveils Oculan Lighting Platform to enhance surgical visualization and illumination

Small Cap

Opinion

AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care

Comments

Stryker

Actualités

Dernières nouvelles pour Stryker (NYSE:SYK) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL